title: Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals.
abstract: Sera mass spectrometry (MS) peak differences were analyzed from 35 ovarian cancer patients and 16 disease-free individuals. "Leave one out" cross validation was used to assign "% cancer peaks" in control and ovarian cancer sera samples. Sera MS discriminated stage I/II and stage III/V ovarian cancer patients versus controls with ROC curve area values of 0.82 and 0.92. Test sensitivities for ovarian cancer stage I/II and III/V were 80% and 93% respectively. These results indicate that MS is useful for distinguishing sera from early-stage ovarian cancer patients, and has potential as a test for early detection of this disease.
authors.affiliation: Department of Biochemistry & Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73104, USA.
authors.forename: James R
authors.initials: JR
authors.lastname: Hocker
authors.forename: Erin A
authors.initials: EA
authors.lastname: Bishop
authors.forename: Stan A
authors.initials: SA
authors.lastname: Lightfoot
authors.forename: Megan R
authors.initials: MR
authors.lastname: Lerner
authors.forename: Marvin D
authors.initials: MD
authors.lastname: Peyton
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Brackett
authors.forename: Rushie J
authors.initials: RJ
authors.lastname: Hanas
authors.forename: D Scott
authors.initials: DS
authors.lastname: McMeekin
authors.forename: Joan L
authors.initials: JL
authors.lastname: Walker
authors.forename: Jay S
authors.initials: JS
authors.lastname: Hanas
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D013058:Mass Spectrometry; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor